Integra LifeSciences Holdings Co. (NASDAQ:IART) Receives Average Rating of “Reduce” from Analysts

Integra LifeSciences Holdings Co. (NASDAQ:IART) has earned an average rating of “Reduce” from the nine analysts that are currently covering the firm, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $29.25.

A number of brokerages recently issued reports on IART. Citigroup downgraded shares of Integra LifeSciences from a “neutral” rating to a “sell” rating and decreased their price target for the stock from $30.00 to $23.00 in a research note on Tuesday, July 30th. StockNews.com downgraded shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a research note on Monday, May 13th. Bank of America cut their price target on Integra LifeSciences from $42.00 to $26.00 and set an “underperform” rating on the stock in a research note on Tuesday, May 7th. BTIG Research cut Integra LifeSciences from a “neutral” rating to a “sell” rating and set a $22.00 price objective for the company. in a research report on Tuesday, July 30th. Finally, Truist Financial cut their target price on Integra LifeSciences from $32.00 to $26.00 and set a “hold” rating on the stock in a research report on Tuesday, July 30th.

Insider Activity

In other Integra LifeSciences news, Chairman Stuart Essig bought 52,641 shares of the business’s stock in a transaction dated Thursday, May 23rd. The shares were acquired at an average cost of $28.49 per share, with a total value of $1,499,742.09. Following the acquisition, the chairman now directly owns 487,922 shares of the company’s stock, valued at approximately $13,900,897.78. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 3.10% of the company’s stock.

Hedge Funds Weigh In On Integra LifeSciences

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Signaturefd LLC grew its stake in shares of Integra LifeSciences by 248.5% in the 4th quarter. Signaturefd LLC now owns 582 shares of the life sciences company’s stock valued at $25,000 after purchasing an additional 415 shares during the last quarter. Blue Trust Inc. increased its stake in Integra LifeSciences by 100.5% in the 2nd quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock valued at $26,000 after buying an additional 444 shares during the period. Hexagon Capital Partners LLC raised its position in Integra LifeSciences by 123.3% during the 4th quarter. Hexagon Capital Partners LLC now owns 670 shares of the life sciences company’s stock worth $29,000 after buying an additional 370 shares during the last quarter. CWM LLC lifted its stake in shares of Integra LifeSciences by 50.8% in the 2nd quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock worth $37,000 after acquiring an additional 425 shares during the period. Finally, Valley National Advisers Inc. purchased a new stake in shares of Integra LifeSciences in the first quarter valued at about $63,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Stock Up 0.4 %

Shares of NASDAQ IART opened at $21.78 on Friday. Integra LifeSciences has a 12-month low of $21.54 and a 12-month high of $45.42. The stock has a market cap of $1.72 billion, a P/E ratio of 43.56, a PEG ratio of 0.84 and a beta of 1.11. The company has a current ratio of 3.39, a quick ratio of 3.35 and a debt-to-equity ratio of 1.17. The business’s fifty day simple moving average is $28.86 and its 200-day simple moving average is $32.71.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings results on Monday, July 29th. The life sciences company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.62 by $0.01. Integra LifeSciences had a return on equity of 14.07% and a net margin of 1.51%. The company had revenue of $418.20 million for the quarter, compared to analyst estimates of $413.07 million. During the same quarter last year, the company earned $0.71 EPS. Integra LifeSciences’s revenue for the quarter was up 9.7% compared to the same quarter last year. As a group, equities analysts predict that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.